hrs4r
Quiero donar

BEGOÑA MARTIN CASTILLO

Personal de plataformas científicas
Firma
BEGOÑA MARTIN-CASTILLO
Posición
Investigador/a Consolidat - R3
Investigador/a Consolidado - R3

Projectes

Codi oficial: PID2022-141955OB-I00 Data inicio:17/10/2023 Data fi: 31/08/2026 Investigador/a principal: JAVIER ABEL MENÉNDEZ MENÉNDEZ Organisme finançador: MINISTERIO DE ECONOMIA E INNOVACION
Codi oficial: PT23/00061 Data inicio:01/01/2024 Data fi: 31/12/2026 Organisme finançador: INSTITUTO DE SALUD CARLOS III

Publicacions

Menendez JA, Cuyàs E, Encinar JA, Steen TV, Verdura S, Llop-Hernández À, López J, Serrano-Hervás E, Osuna S, Martin-Castillo B, Lupu R

Fatty acid synthase (FASN) signalome: A molecular guide for precision oncology

MOLECULAR ONCOLOGY, 2024, 18, 479-516 dx.doi.org/10.1002/1878-0261.13582
Verdura S, Encinar JA, Gratchev A, Llop-Hernández À, López J, Serrano-Hervás E, Teixidor E, López-Bonet E, Martin-Castillo B, Micol V, Bosch-Barrera J, Cuyàs E, Menendez JA

Silibinin is a suppressor of the metastasis-promoting transcription factor ID3

Phytomedicine, 2024, 128, 155493-155493 dx.doi.org/10.1016/j.phymed.2024.155493
Cuyàs E, Pedarra S, Verdura S, Pardo MA, Espin Garcia R, Serrano-Hervás E, Llop-Hernández À, Teixidor E, Bosch-Barrera J, López-Bonet E, Martin-Castillo B, Lupu R, Pujana MA, Sardanyès J, Alarcón T, Menendez JA

Fatty acid synthase (FASN) is a tumor-cell-intrinsic metabolic checkpoint restricting T-cell immunity.

Cell Death Discovery, 2024, 10, 417-417 dx.doi.org/10.1038/s41420-024-02184-z
Cuyàs, E, Verdura, S, Martin-Castillo, B, Menendez, JA

Circulating levels of MOTS-c in patients with breast cancer treated with metformin

Aging-Us, 2023, 15, 892-897
Bosch-Barrera J, Roqué A, Teixidor E, Carmona-Garcia MC, Arbusà A, Brunet J, Martin-Castillo B, Cuyàs E, Verdura S, Menendez JA

Clinical Management of COVID-19 in Cancer Patients with the STAT3 Inhibitor Silibinin

Pharmaceuticals, 2022, 15 dx.doi.org/10.3390/ph15010019
Cuyàs E, Martin-Castillo B, Menendez JA

Metformin and breast cancer: an opportunity for pharmacogenetics

Aging-Us, 2022, 14, 5612-5613 dx.doi.org/10.18632/aging.204180
Cejuela M, Martin-Castillo B, Menendez JA, Pernas S

Metformin and Breast Cancer: Where Are We Now?

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 dx.doi.org/10.3390/ijms23052705
Tramonti A, Cuyàs E, Encinar JA, Pietzke M, Paone A, Verdura S, Arbusà A, Martin-Castillo B, Giardina G, Joven J, Vazquez A, Contestabile R, Cutruzzolà F, Menendez JA

Metformin Is a Pyridoxal-5 '-phosphate (PLP)-Competitive Inhibitor of SHMT2

Cancers, 2021, 13 dx.doi.org/10.3390/cancers13164009
Cuyàs E, Verdura S, Martin-Castillo B, Menendez JA

Metformin: Targeting the Metabolo-Epigenetic Link in Cancer Biology

Frontiers in oncology, 2021, 10, 620641-620641 dx.doi.org/10.3389/fonc.2020.620641
Cuyàs E, Verdura S, Martin-Castillo B, Alarcón T, Lupu R, Bosch-Barrera J, Menendez JA

Tumor Cell-Intrinsic Immunometabolism and Precision Nutrition in Cancer Immunotherapy

Cancers, 2020, 12 dx.doi.org/10.3390/cancers12071757

Formulari de contacte

Conoce el IDIBGI!

menu